e.g. mhealth
Search Results (1 to 3 of 3 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 1 JMIR Formative Research
- 1 JMIR Research Protocols
- 1 JMIR mHealth and uHealth
- 0 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Go back to the top of the page Skip and go to footer section
Reference 4: Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised Reference 35: Hydroxycarbamide adherence and cumulative dose associated with hospital readmission inhydroxycarbamide
JMIR Res Protoc 2020;9(7):e16319
Download Citation: END BibTex RIS
Hydroxyurea (also known as hydroxycarbamide) is a medication approved by the US Food and Drug Administration (FDA) that has several health benefits and is cost-effective in pediatric and adult patients with SCD [7-19]. Hydroxyurea induces fetal hemoglobin production, thereby decreasing sickle hemoglobin erythrocyte polymers, hemolysis, and vaso-occlusion [10,11].
JMIR Mhealth Uhealth 2020;8(5):e14884
Download Citation: END BibTex RIS